AKARI THERAPEUTICS, PLC
Get an alert when AKARI THERAPEUTICS, PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£3.9M
USD 5,203,000
+100.2% highest in 3 filed years
Net assets
£13M
USD 17,233,000
-25.3% vs 2024
Employees
8
-20% lowest in 3 filed years
Profit before tax
-£23M
USD -31,344,000
-50.4% lowest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
Management has concluded that these outcomes represent material uncertainties that cast significant doubt regarding the Group's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.
-
Going-concern uncertainty disclosed
Net assets
3-year trend · vs Industrials median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | — | — | — | — | |
| Operating profit | -£15,302,440 | -£17,036,982 | -£22,696,511 | -33.2% | |
| Profit before tax | -£10,053,152 | -£15,604,132 | -£23,464,591 | -50.4% | |
| Net profit | -£9,163,048 | -£15,241,803 | -£21,883,515 | -43.6% | |
| Cash | £2,878,425 | £1,945,651 | £3,895,044 | +100.2% | |
| Total assets less current liabilities | £739,632 | £23,574,637 | — | — | |
| Net assets | £739,632 | £17,269,052 | £12,900,883 | -25.3% | |
| Equity | £739,632 | £17,269,052 | £12,900,883 | -25.3% | |
| Average employees | 18 | 10 | 8 | -20% | |
| Wages | £3,189,849 | £1,325,049 | £1,315,317 | -0.7% | |
| Directors' remuneration | £1,164,096 | £404,252 | £513,550 | +27% |
Figures converted to GBP from USD at 0.749 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Return on capital employed | — | -72.3% | — | |
| Gearing (liabilities / total assets) | 82.3% | 55.1% | 52.1% | |
| Current ratio | 1.21x | 0.17x | 0.45x | |
| Interest cover | — | — | -31.98x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 4 times since incorporation
- AKARI THERAPEUTICS, PLC 2015-09-17 → present
- CELSUS THERAPEUTICS PLC 2013-06-25 → 2015-09-17
- MORRIA BIOPHARMACEUTICALS PLC 2005-02-15 → 2013-06-25
- MORRIA BIOPHARMACEUTICALS LIMITED 2005-01-19 → 2005-02-15
- FRESHNAME NO.333 LIMITED 2004-10-07 → 2005-01-19
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- HaysMac LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“Management has concluded that these outcomes represent material uncertainties that cast significant doubt regarding the Group's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.”
Group structure
- AKARI THERAPEUTICS, PLC · parent
- Volution Immuno Pharmaceuticals SA 100%
- Celsus Therapeutics Inc. 100%
- Morria Biopharma Ltd. 100%
- Akari Malta Limited 100%
- Peak Bio Incorporated 100%
- Peak Bio Corporation Limited 100%
- Ignyte Korea Corporation Limited 100%
- Peak Bio California Incorporated 100%
Significant events
- “On 14 November 2024, the Group completed the previously announced business combination contemplated by the Agreement and Plan of Merger...with Peak Bio surviving such merger as the Group's wholly owned subsidiary.”
- “On 17 March 2026, the Company announced a change in the ratio of its American Depositary Shares ("ADSs") to ordinary shares... The ADS Ratio Change became effective on 31 March 2026...”
- “On 21 May 2026, the Company announced the pricing of a $5.5 million private placement of ADS's and warrants. Proceeds will be used for working capital and general corporate purposes, including advancement of its lead ADC programme, AKTX-101.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
8 active · 27 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| PRISM COSEC LIMITED | Corporate Secretary | 2018-08-20 | — | — |
| BAZEMORE, Robert | Director | 2024-09-17 | Oct 1967 | American |
| GASLIGHTWALA, Abizer | Director | 2024-12-16 | Jun 1973 | American |
| HUH, Hoyoung | Director | 2024-11-14 | May 1969 | American |
| NEAL, James | Director | 2024-11-14 | Nov 1955 | American |
| PATEL, Samir Rashmikant | Director | 2023-11-29 | Oct 1969 | American |
| PATEL, Sandip | Director | 2024-11-14 | Nov 1966 | American |
| PRUDO-CHLEBOSZ, Raymond, Dr | Director | 2015-09-16 | Nov 1944 | Canadian |
Show 27 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ELEFANT, Dov | Secretary | 2017-12-04 | 2019-09-09 |
| SHAW, Robert Morrow | Secretary | 2016-03-23 | 2017-12-04 |
| SLC CORPORATE SERVICES LIMITED | Corporate Secretary | 2004-12-21 | 2018-08-20 |
| SLC REGISTRARS LIMITED | Corporate Secretary | 2004-10-07 | 2004-12-21 |
| BYRNE, David Anthony | Director | 2016-04-20 | 2023-06-30 |
| COHEN, Mark | Director | 2004-12-21 | 2016-10-13 |
| COHEN, Yuval | Director | 2005-01-12 | 2013-12-10 |
| DOMAN, Robert Francis | Director | 2013-06-20 | 2015-07-15 |
| EIRAN, Amos | Director | 2012-06-28 | 2015-07-15 |
| FELDSCHREIBER, Peter, Doctor | Director | 2018-01-23 | 2022-06-03 |
| GRISSINGER, Michael | Director | 2018-01-23 | 2024-12-16 |
| HASHAD, Mohamed Wa’El Ahmed | Director | 2023-06-30 | 2024-11-14 |
| HILL, James Ferguson, Dr | Director | 2015-09-17 | 2023-06-30 |
| JACQUES, Rachelle Suzanne | Director | 2022-03-28 | 2024-05-07 |
| LAU, Johnson, Dr | Director | 2007-05-02 | 2015-09-17 |
| PRICE, Fredric | Director | 2013-06-20 | 2014-06-19 |
| RADAY, Gilead | Director | 2005-06-14 | 2013-06-20 |
| RICHARDSON, Clive Stuart | Director | 2015-09-16 | 2022-03-28 |
| ROSHWALB, Gur-Arye Yehuda, Dr. | Director | 2014-06-19 | 2017-05-30 |
| SHAW, Allan Lee | Director | 2013-10-02 | 2016-06-29 |
| SIDRANSKY, David, Dr | Director | 2007-05-02 | 2015-09-17 |
| SOLOMON, David Horn | Director | 2017-08-28 | 2018-05-08 |
| UNGAR, Stuart Charles | Director | 2015-09-17 | 2023-06-30 |
| WARD, Robert Eugene | Director | 2016-10-13 | 2018-09-19 |
| WILLIAMS, Donald Allen | Director | 2016-06-29 | 2024-11-14 |
| YEDGAR, Saul, Professor | Director | 2005-01-28 | 2014-03-25 |
| SLC CORPORATE SERVICES LIMITED | Corporate Director | 2004-10-07 | 2004-12-21 |
Ownership
Persons with significant control
Filing timeline
Last 20 of 333 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-12-27 MA Memorandum articles
- 2025-12-27 RESOLUTIONS Resolution
- 2025-07-22 RESOLUTIONS Resolution
- 2024-11-30 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-22 | AA | accounts | Accounts with accounts type group | |
| 2026-05-09 | SH01 | capital | Capital allotment shares | |
| 2026-05-09 | SH01 | capital | Capital allotment shares | |
| 2026-01-14 | SH02 | capital | Capital alter shares subdivision | |
| 2025-12-30 | SH03 | capital | Capital return purchase own shares | |
| 2025-12-29 | SH06 | capital | Capital cancellation shares | |
| 2025-12-27 | SH01 | capital | Capital allotment shares | |
| 2025-12-27 | MA | incorporation | Memorandum articles | |
| 2025-12-27 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-15 | SH01 | capital | Capital allotment shares | |
| 2025-10-07 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-10-07 | CH01 | officers | Change person director company with change date | |
| 2025-07-22 | RESOLUTIONS | resolution | Resolution | |
| 2025-07-16 | SH01 | capital | Capital allotment shares | |
| 2025-06-12 | AA | accounts | Accounts with accounts type group | |
| 2025-06-06 | SH01 | capital | Capital allotment shares | |
| 2025-06-05 | SH01 | capital | Capital allotment shares | |
| 2025-05-13 | TM01 | officers | Termination director company with name termination date | |
| 2025-05-13 | AP01 | officers | Appoint person director company with name date | |
| 2024-11-30 | RESOLUTIONS | resolution | Resolution |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 14
- Capital events
- 10
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.